Company profile
COHERUS ONCOLOGY, INC.
NASDAQ:CHRSBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| LOQTORZI | approved | — | 0 | — |
| CASDOZOKITUG | phase2 | — | 2 | active |
| TAGMOKITUG | phase1 | — | 2 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (17)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02486939 | phase3 | completed | 2015-07-01 | 2017-09-01 | Coherus Oncology, Inc. | A Long Term Safety Extension Study (CHS-0214-05) |
| NCT06389526 | phase1 | not_yet_recruiting | 2025-02-15 | 2028-05-30 | Coherus Oncology, Inc. | A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors |
| NCT06657144 | phase1 | recruiting | 2025-04-01 | 2028-01-01 | Coherus Oncology, Inc. | A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors |
| NCT06457503 | phase4 | recruiting | 2024-11-01 | 2027-12-01 | Coherus Oncology, Inc. | A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer |
| NCT06679985 | phase2 | active_not_recruiting | 2024-12-20 | 2027-09-01 | Coherus Oncology, Inc. | A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| BLA 761240 | 2023-10-27 | BLA | COHERUS BIOSCIENCES, INC. | |||||
Loading… | ||||||||